News

Rexahn Pharma said that the patent covers neurotherapeutic pharmaceutical formulation for cefazoline sulfone, cefazoline sulfoxide, ceftriaxone sulfoxide, and ceftriaxone sulfone for treating neurological disease and behavioral and cognitive

The lead product associated with the arrangement is ARC19499, a synthetic, subcutaneously-administered hemophilia therapy currently in a Phase I clinical trial in the UK. Baxter said that ARC19499

Medgenics has signed a preclinical development and option agreement with the international biopharmaceutical company worth up to $7m in payments that included funding for preclinical development of Medgenics’

ImmunGene’s technology empowers monoclonal antibodies targeted to tumor cells by fusing them to immune effector molecules; that is, cytokine, chemokine and co-stimulatory molecules, thereby combining the specificity of

FDA said that the sildenafil may interact with prescription drugs known as nitrates, including nitroglycerin and can dangerously lower blood pressure. The FDA is investigating the reported death

The UK regulatory agency has approved Bafna for the manufacturing of Finasteride in strength of 5 mg. Finasteride is an antiandrogen which acts by inhibiting 5-alpha reductase, the

ORCA was designed to reflect real world conditions when managing PPR in a large, diverse population of rosacea patients undergoing routine care at 271 community-based medical practices. Galderma

Rockwell’s data from the company’s Phase IIb dose ranging clinical trial demonstrated a 13% dose reduction in ESA and 0.79g/dL increase in hemoglobin compared to placebo in the

Xanodyne Pharma said that the withdrawal is part of a market-wide withdrawal applying to all propoxyphene-containing products, affecting branded and generic pharmaceutical companies and a number of products